6-Amino-5-Bromoquinoxaline CAS 50358-63-9 Purity >99.0% (HPLC) Brimonidine Tartrate Intermediate

6-Amino-5-Bromoquinoxaline (CAS: 50358-63-9) is an important intermediate of quinoxaline derivatives. 6-Amino-5-Bromoquinoxaline is used as a pharmaceutical intermediate, an intermediate of Brimonidine Tartrate (CAS: 70359-46-5). Brimonidine is a highly selective α2-receptor blocker, successfully developed by the US Company Allergan, which is an eye medication. It can reduce intraocular pressure (IOP). Brimonidine Tartrate ophthalmic solution saling in the market is brimonidine tartrate form, which is a good IOP-lowering medication for chronic open-angle glaucoma and ocular hypertension treatment of patients, but also for argon laser IOP levels. Brimonidine Tartrate ophthalmic solution has a dual mechanism of action by reducing aqueous humor production and increasing the pigment layer of liquid scleral outflow therapeutic purposes. After dropping into the eye, the effect is rapid, and it can reach the peak when using up to 2h, and the effective time can maintain 12h. Blood can only detect traces of drugs. This product has first-pass metabolism in the liver, and metabolites excreted in the urine by the kidneys. Systemic absorption and distribution are not affected, and the elderly do not need dose adjustment. Brimonidine Tartrate ophthalmic solution compared with other α-blockers, the fat-soluble is small, while it does not easy to pass through blood-brain barrier and does not produce sedation, hypotension and other similar clonidine central adverse reactions.